Skip to main content
. Author manuscript; available in PMC: 2021 Mar 28.
Published in final edited form as: Oncogene. 2020 Sep 28;39(45):6935–6949. doi: 10.1038/s41388-020-01479-6

Figure 3: Characterization of LvCaP-2 and LvCaP-2R.

Figure 3:

a) H & E histology (200x) of LvCaP-2 (inset, 400x). IHC (200x) for b) AR (inset, AR immunoblot), c) c-Myc, d) Ki67, e) HoxB13, f) Nkx3.1, g) cytokeratin-18, and h) PSA. i) Growth rate of LvCaP-2 in intact (i.e. ADT-equivalent) mice with subsequent regression and relapse in castrate (i.e. ARSi-equivalent) male NSG mice (n = 5 each). j) Growth rate of LvCaP-2R in intact vs. castrate hosts (n = 5 each). k) Abi resistance of LvCaP-2R xenografts in vivo (n = 3). i) H & E histology (200x) of LvCaP-2R (inset, 400x). IHC (200x) for m) Nkx3.1 and n) AR in LvCaP-2R PDX in castrate hosts. o) AR immunoblot of LvCaP-2 vs. LvCaP-2R and quantification based on densitometry. p) LvCaP-2R resistance to daily oral Enzalutamide treatment.